| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
Kaempferol-3-neohesperidoside targets multiple signaling pathways involved in glucose metabolism. It stimulates glucose uptake in skeletal muscle via the PI3K and PKC pathways. The effect on glucose uptake is completely nullified by pretreatment with LY294002 (a PI3K inhibitor) and RO318220 (a PKC inhibitor), confirming the involvement of these pathways. The compound also stimulates glycogen synthesis via the PI3K-GSK-3 pathway and MAPK-PP1 pathway. It also targets MEK, GSK-3, and MAPK pathways.
|
|---|---|
| ln Vitro |
In vitro, Kaempferol-3-neohesperidoside stimulates glucose uptake in rat soleus muscle by 35% at 1 nM and 21% at 100 nM. This effect is mediated through the PI3K and PKC pathways, as confirmed by inhibition studies with specific inhibitors. The compound also stimulates glycogen synthesis via PI3K-GSK-3 and MAPK-PP1 pathways. Molecular docking studies suggest strong binding affinity to acetylcholinesterase (AChE1). These activities confirm its potential for studying glucose metabolism and related disorders.
|
| ln Vivo |
Specific in vivo data for Kaempferol-3-neohesperidoside are limited in the available literature. Given its potent glucose uptake stimulation in isolated rat soleus muscle ex vivo, the compound has potential for in vivo efficacy studies in animal models of diabetes and metabolic syndrome. Such studies would involve oral or intraperitoneal administration of the compound to diabetic or insulin-resistant rodents, followed by measurements of blood glucose levels, glucose tolerance tests, and insulin sensitivity assessments.
|
| Enzyme Assay |
The glucose uptake assay is performed using isolated rat soleus muscle. Rats are euthanized, and the soleus muscles are dissected and incubated in oxygenated Krebs-Henseleit buffer containing various concentrations of Kaempferol-3-neohesperidoside (e.g., 1-100 nM) for a defined period. Glucose uptake is measured using [³H]-2-deoxyglucose or [¹⁴C]-glucose, and the rate of uptake is calculated. To confirm pathway involvement, muscles are pre-incubated with specific inhibitors such as LY294002 (PI3K inhibitor) or RO318220 (PKC inhibitor).
|
| Cell Assay |
For cellular studies, skeletal muscle cells such as C2C12 myotubes or L6 myotubes are cultured in appropriate media. Cells are serum-starved and treated with Kaempferol-3-neohesperidoside at various concentrations. Glucose uptake is measured using fluorescent glucose analogs (e.g., 2-NBDG) or radiolabeled glucose. Signaling pathway activation is assessed by Western blot for phosphorylated PI3K, Akt, PKC, GSK-3, and MAPK. Glycogen synthesis is measured by [¹⁴C]-glucose incorporation into glycogen.
|
| Animal Protocol |
In vivo efficacy studies for glucose-lowering compounds are conducted in rodent models of diabetes. Streptozotocin-induced diabetic mice or db/db mice are treated with Kaempferol-3-neohesperidoside via oral gavage or intraperitoneal injection at appropriate doses. Blood glucose levels are measured at various time points using a glucometer. Oral glucose tolerance tests (OGTT) are performed after compound administration. Insulin sensitivity may be assessed by insulin tolerance tests (ITT). Tissues are harvested for analysis of signaling pathway activation and glycogen content.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for Kaempferol-3-neohesperidoside are not reported. As a flavonoid glycoside with molecular weight approximately 594 g/mol, the compound is expected to have limited oral bioavailability due to poor membrane permeability and extensive intestinal metabolism (deglycosylation). The aglycone (kaempferol) may be absorbed and undergo further metabolism. Pharmacokinetic studies would be required to determine the compound's absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for Kaempferol-3-neohesperidoside are limited. As a flavonoid glycoside from dietary sources (Primula species), the compound is generally considered to have a moderate safety profile. However, comprehensive toxicology studies have not been reported. The compound should be handled with appropriate safety precautions in laboratory settings.
|
| References | |
| Additional Infomation |
Kaempferol-3-neohesperidin belongs to the flavonoid family and is a glycoside. It has been reported to exist in persimmon (Diospyros cathayensis), soybean (Glycine max), and other organisms with relevant data.
Kaempferol-3-neohesperidoside is a flavonoid glycoside that stimulates glucose uptake in rat soleus muscle via PI3K and PKC pathways (35% at 1 nM) and glycogen synthesis via PI3K-GSK-3 and MAPK-PP1 pathways. No clinical trials or approvals exist. For research use only. |
| Molecular Formula |
C27H30O15
|
|---|---|
| Molecular Weight |
594.5181
|
| Exact Mass |
594.158
|
| Elemental Analysis |
C, 54.55; H, 5.09; O, 40.37
|
| CAS # |
32602-81-6
|
| PubChem CID |
5318761
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
945.5±65.0 °C at 760 mmHg
|
| Flash Point |
314.1±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.744
|
| LogP |
2.66
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
42
|
| Complexity |
985
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@@H](CO)O[C@H]2OC3=C(C4=CC=C(C=C4)O)OC5=CC(=CC(=C5C3=O)O)O)O)O)O)O)O
|
| InChi Key |
OHOBPOYHROOXEI-JWMUNMLDSA-N
|
| InChi Code |
InChI=1S/C27H30O15/c1-9-17(32)20(35)22(37)26(38-9)42-25-21(36)18(33)15(8-28)40-27(25)41-24-19(34)16-13(31)6-12(30)7-14(16)39-23(24)10-2-4-11(29)5-3-10/h2-7,9,15,17-18,20-22,25-33,35-37H,8H2,1H3/t9-,15+,17-,18+,20+,21-,22+,25+,26-,27-/m0/s1
|
| Chemical Name |
3-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one
|
| Synonyms |
OWN-02816; OWN02816; OWN 02816; Kaempferol 3-O-β-neohesperidoside; Kaempferol 3 neohesperidoside; Kaempferol 3-neohesperidoside
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~84.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.21 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6820 mL | 8.4101 mL | 16.8203 mL | |
| 5 mM | 0.3364 mL | 1.6820 mL | 3.3641 mL | |
| 10 mM | 0.1682 mL | 0.8410 mL | 1.6820 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
